ATE429217T1 - Nateglinid enthaltende hydrophile arzneimittelpräparate - Google Patents

Nateglinid enthaltende hydrophile arzneimittelpräparate

Info

Publication number
ATE429217T1
ATE429217T1 AT01976818T AT01976818T ATE429217T1 AT E429217 T1 ATE429217 T1 AT E429217T1 AT 01976818 T AT01976818 T AT 01976818T AT 01976818 T AT01976818 T AT 01976818T AT E429217 T1 ATE429217 T1 AT E429217T1
Authority
AT
Austria
Prior art keywords
preparation
nateglinide
hydrophilic
preparations containing
medicinal preparations
Prior art date
Application number
AT01976818T
Other languages
English (en)
Inventor
Nobutaka Ninomiya
Chisato Makino
Akira Yabuki
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of ATE429217T1 publication Critical patent/ATE429217T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01976818T 2000-10-24 2001-10-23 Nateglinid enthaltende hydrophile arzneimittelpräparate ATE429217T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000324374 2000-10-24
PCT/JP2001/009292 WO2002040010A1 (fr) 2000-10-24 2001-10-23 Preparations de medicament contenant du nateglinide

Publications (1)

Publication Number Publication Date
ATE429217T1 true ATE429217T1 (de) 2009-05-15

Family

ID=18801919

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01976818T ATE429217T1 (de) 2000-10-24 2001-10-23 Nateglinid enthaltende hydrophile arzneimittelpräparate

Country Status (19)

Country Link
US (1) US20040029968A1 (de)
EP (1) EP1334721B1 (de)
JP (3) JPWO2002040010A1 (de)
KR (1) KR100829410B1 (de)
CN (1) CN100531730C (de)
AT (1) ATE429217T1 (de)
AU (1) AU2001296000A1 (de)
BR (1) BR0114897A (de)
CA (1) CA2426764C (de)
CY (1) CY1110320T1 (de)
DE (1) DE60138476D1 (de)
DK (1) DK1334721T3 (de)
ES (1) ES2321911T3 (de)
MX (1) MXPA03003686A (de)
PT (1) PT1334721E (de)
RU (1) RU2283104C2 (de)
SI (1) SI1334721T1 (de)
TW (1) TWI289461B (de)
WO (1) WO2002040010A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002120498A (ru) * 1999-12-28 2004-04-10 Адзиномото Ко., Инк. (Jp) Противодиабетический препарат для перорального введения
RU2271805C2 (ru) * 2000-10-24 2006-03-20 Адзиномото Ко., Инк. Препарат, содержащий натеглинид
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2005020979A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions of nateglinide
US20070219250A1 (en) * 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
WO2005092319A1 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
JP5168712B2 (ja) * 2004-04-01 2013-03-27 味の素株式会社 ナテグリニド含有製剤
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
WO2013066278A1 (en) * 2011-11-03 2013-05-10 Mahmut Bilgic A process for production of pharmaceutical formulations comprising nateglinide
EP2809316A1 (de) * 2012-01-31 2014-12-10 Mahmut Bilgic Synergistische kombination aus einem meglitinidderivat und liponsäure

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066532B2 (ja) * 1983-09-29 1994-01-26 日産化学工業株式会社 親水性コロイドにより変性したワックス性微粉末
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5474989A (en) * 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
DE10199058I2 (de) * 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
JPH0696517B2 (ja) * 1993-03-17 1994-11-30 日産化学工業株式会社 変性したワックス性微粉末で被覆された薬剤及びその製造法
JP2994956B2 (ja) * 1994-05-31 1999-12-27 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、その組成物およびその錠剤
ES2257772T3 (es) * 1996-11-15 2006-08-01 Ajinomoto Co., Inc. Preparacion de nateglinida en comprimidos.
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
JP3591801B2 (ja) * 1997-06-19 2004-11-24 田辺製薬株式会社 口腔内速崩壊性製剤の製法
JP2000178183A (ja) * 1998-12-17 2000-06-27 Lion Corp 固形製剤及びその製造方法
JP2000290171A (ja) * 1999-04-06 2000-10-17 Eisai Co Ltd 崩壊のはやい錠剤又はその製造方法
RU2002120498A (ru) * 1999-12-28 2004-04-10 Адзиномото Ко., Инк. (Jp) Противодиабетический препарат для перорального введения
EP1283054A4 (de) * 2000-03-17 2006-04-12 Ajinomoto Kk Medikamente zur behandlung von komplikationen des diabetes und neuropathien, und verwendung davon
CN1273442C (zh) * 2000-10-18 2006-09-06 味之素株式会社 酰基苯丙氨酸的制备方法
PT1334963E (pt) * 2000-10-18 2007-09-20 Ajinomoto Kk Processo para a produção de cristais de nateglinida
CA2426745C (en) * 2000-10-24 2009-09-15 Ajinomoto Co., Inc. Methods for producing nateglinide b-type crystals
RU2271805C2 (ru) * 2000-10-24 2006-03-20 Адзиномото Ко., Инк. Препарат, содержащий натеглинид
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration

Also Published As

Publication number Publication date
EP1334721B1 (de) 2009-04-22
RU2283104C2 (ru) 2006-09-10
CA2426764A1 (en) 2003-04-23
JP2013064018A (ja) 2013-04-11
EP1334721A1 (de) 2003-08-13
AU2001296000A1 (en) 2002-05-27
CA2426764C (en) 2010-04-20
JP2010095551A (ja) 2010-04-30
JPWO2002040010A1 (ja) 2004-06-03
PT1334721E (pt) 2009-06-01
BR0114897A (pt) 2003-08-12
JP5278708B2 (ja) 2013-09-04
SI1334721T1 (sl) 2009-08-31
CN100531730C (zh) 2009-08-26
WO2002040010A1 (fr) 2002-05-23
ES2321911T3 (es) 2009-06-15
DK1334721T3 (da) 2009-07-06
CN1482904A (zh) 2004-03-17
KR100829410B1 (ko) 2008-05-15
MXPA03003686A (es) 2004-01-26
CY1110320T1 (el) 2015-01-14
KR20030042028A (ko) 2003-05-27
JP5673972B2 (ja) 2015-02-18
US20040029968A1 (en) 2004-02-12
TWI289461B (en) 2007-11-11
EP1334721A4 (de) 2005-11-02
DE60138476D1 (de) 2009-06-04

Similar Documents

Publication Publication Date Title
CY1110320T1 (el) Παρασκευασματα υδροφιλου φαρμακου περιεχοντα νατεγλινιδη (nateglinide)
ES2528359T3 (es) Procedimiento para la producción de una forma medicamentosa oral con desintegración y puesta en libertad inmediatas de las sustancias activas
BR9908121A (pt) Forma galênica de liberação imediata e de liberação prolongada administrável por via oral compreendendo um agente estimulador de absorção e utilização deste agente estimulador de absorção
ES2354244T3 (es) Proceso de preparación de formas de administración rápidamente disgregables para la liberación de principios activos en la cavidad bucal o en cavidades corporales.
ES2097670T5 (es) Emulsion limpiadora de aceite en agua que tiene el aspecto de una leche.
AR029716A1 (es) Productos dermatologicos en forma de hoja
CA2416869A1 (en) Vaccines
JP4387356B2 (ja) 超音波導入スキンケアデバイス
ES2075249T3 (es) Dispositivo adhesivo para la administracion transdermica de un agente activo.
KR101489524B1 (ko) 발포성 보습 조성물
ATE123218T1 (de) Pharmazeutische ionenaustauscherharzzusammensetzung.
KR20040002391A (ko) 경구투여제 및 경구투여제 유지체
DE69414840D1 (de) Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
RU2000123567A (ru) Фармацевтическая композиция, содержащая в комбинации метформин и фибрат, и ее применение при приготовлении лекарственных средств, предназначенных для снижения гипергликемии
IT1246188B (it) Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
ES2193726T3 (es) Formulaciones de aerosol medicinales.
CA2320039A1 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
CA2617659A1 (en) Use of hydroxybenzoic acid esters and analogues for the manufacture of a medicament for the prevention and treatment of virus infection
RU2003111949A (ru) Гидрофильный фармацевтический препарат, содержащий натеглинид
CO4700033A1 (es) Preparados de liberacion controlada a base de una sal pota- sica alcalinizante
DE59509928D1 (de) Antihyperglykämisch wirksame Arzneimittel
ATE262350T1 (de) Flüssige pharmazeutische zusammensetzung zur oralen verabreichung bitterschmeckender hydrolyseempfindlicher aktivstoffe
JP2003081840A (ja) 清涼化方法、清涼化剤および外用組成物
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1334721

Country of ref document: EP